Pharmacologic prevention of migraine.
作者信息
Tzankova Velina, Becker Werner J, Chan Tommy L H
机构信息
Division of Neurology, Department of Medicine (Tzankova), University of Toronto, Toronto, Ont.; Department of Clinical Neurosciences and Hotchkiss Brain Institute (Becker), Cumming School of Medicine, University of Calgary, Calgary, Alta.; Department of Clinical Neurological Sciences (Chan), Western University, London, Ont.
出版信息
CMAJ. 2023 Feb 6;195(5):E187-E192. doi: 10.1503/cmaj.221607.
Abstract
摘要
相似文献
1
Pharmacologic prevention of migraine.偏头痛的药物预防
CMAJ. 2023 Feb 6;195(5):E187-E192. doi: 10.1503/cmaj.221607.
2
Pharmacologic management of acute attacks of migraine and prevention of migraine headache.偏头痛急性发作的药物治疗及偏头痛的预防
Ann Intern Med. 2002 Nov 19;137(10):840-9. doi: 10.7326/0003-4819-137-10-200211190-00014.
3
Valproic acid: a migraine prophylaxis alternative.丙戊酸：一种偏头痛预防的替代药物。
Ann Pharmacother. 1996 Jul-Aug;30(7-8):865-6. doi: 10.1177/106002809603000726.
4
Topiramate for chronic migraine.托吡酯用于慢性偏头痛。
Headache. 2007 Jan;47(1):139. doi: 10.1111/j.1526-4610.2007.00667.x.
5
Treatment of chronic migraine.慢性偏头痛的治疗。
Curr Pain Headache Rep. 2011 Feb;15(1):64-9. doi: 10.1007/s11916-010-0159-x.
6
Drugs for migraine.偏头痛药物。
Treat Guidel Med Lett. 2011 Feb;9(102):7-12; quiz 14.
7
Summaries for patients. Guidelines for the treatment and prevention of migraine headaches.患者摘要。偏头痛治疗与预防指南。
Ann Intern Med. 2002 Nov 19;137(10):I50. doi: 10.7326/0003-4819-137-10-200211190-00005.
8
Valproate for Adult Migraine Prophylaxis.丙戊酸盐用于成人偏头痛的预防。
Am Fam Physician. 2016 Nov 1;94(9):Online.
9
Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society.基于证据的指南更新：成人发作性偏头痛预防的药物治疗：美国神经病学学会和美国头痛学会质量标准小组委员会的报告。
Neurology. 2012 Apr 24;78(17):1337-45. doi: 10.1212/WNL.0b013e3182535d20.
10
Migraine prophylaxis: who, why, and how.偏头痛的预防：对象、原因及方法。
Cleve Clin J Med. 2006 Sep;73(9):793-4, 797, 800-1 passim. doi: 10.3949/ccjm.73.9.793.
引用本文的文献
1
Noninvasive Vagus Nerve Stimulation for Cluster Headache and Migraine: A Health Technology Assessment.用于丛集性头痛和偏头痛的非侵入性迷走神经刺激：一项卫生技术评估
Ont Health Technol Assess Ser. 2025 May 1;25(2):1-177. eCollection 2025.
2
CROATIAN GUIDELINES FOR SPECIFIC PREVENTIVE TREATMENT OF MIGRAINE WITH MONOCLONAL ANTIBODIES TARGETING CALCITONIN GENE-RELATED PEPTIDE (CGRP) (EPTINEZUMAB, FREMANEZUMAB, AND GALCANEZUMAB) OR THE CGRP RECEPTOR (ERENUMAB).克罗地亚使用靶向降钙素基因相关肽（CGRP）的单克隆抗体（eptinezumab、fremanezumab和galcanezumab）或CGRP受体（erenumab）对偏头痛进行特定预防性治疗的指南
Acta Clin Croat. 2024 Oct;63(2):436-450. doi: 10.20471/acc.2024.63.02.22.
3
Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine.MEDI0618，一种靶向PAR2的pH依赖性单克隆抗体，在偏头痛临床前模型中的疗效。
Brain. 2025 Apr 3;148(4):1345-1359. doi: 10.1093/brain/awae344.
4
Healthcare Utilization, Costs, and Treatment Discontinuation in Adults with Episodic Migraine Initiating Galcanezumab Versus Rimegepant: A US Retrospective Claims Analysis.发作性偏头痛成人患者起始使用加卡尼单抗与利美吉泮的医疗保健利用、成本及治疗中断情况：一项美国回顾性索赔分析
Adv Ther. 2025 Feb;42(2):918-934. doi: 10.1007/s12325-024-03072-9. Epub 2024 Dec 16.
5
Patient preferences for preventive migraine treatments among Canadian adults: A discrete choice experiment.加拿大成年人对预防性偏头痛治疗的偏好：一项离散选择实验。
Headache. 2025 Jan;65(1):113-123. doi: 10.1111/head.14781. Epub 2024 Jul 9.
6
Neurasites-A Standardized Plant Extract in the Treatment and Prevention of Migraine Attacks.神经通——一种用于治疗和预防偏头痛发作的标准化植物提取物。
J Clin Med. 2024 Jun 7;13(12):3364. doi: 10.3390/jcm13123364.
7
Anti-CGRP and Anti-CGRP Receptor Monoclonal Antibodies for Migraine Prophylaxis: Retrospective Observational Study on 209 Patients.用于偏头痛预防的抗降钙素基因相关肽和抗降钙素基因相关肽受体单克隆抗体：对209例患者的回顾性观察研究
J Clin Med. 2024 Feb 17;13(4):1130. doi: 10.3390/jcm13041130.
8
Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan.偏头痛患者的治疗模式和特征：来自日本回顾性数据库研究的结果。
J Headache Pain. 2024 Feb 8;25(1):19. doi: 10.1186/s10194-024-01722-5.
9
[Not Available].[无可用内容]
CMAJ. 2023 Apr 11;195(14):E524-E530. doi: 10.1503/cmaj.211969-f.
10
Diagnosis and acute management of migraine.偏头痛的诊断与急性处理
CMAJ. 2023 Jan 30;195(4):E153-E158. doi: 10.1503/cmaj.211969.
本文引用的文献
1
Diagnosis and acute management of migraine.偏头痛的诊断与急性处理
CMAJ. 2023 Jan 30;195(4):E153-E158. doi: 10.1503/cmaj.211969.
2
Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.依瑞奈尤单抗对比托吡酯预防偏头痛的疗效 - 一项随机、双盲、阳性药物对照的 4 期临床试验。
Cephalalgia. 2022 Feb;42(2):108-118. doi: 10.1177/03331024211053571. Epub 2021 Nov 7.
3
Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis.托吡酯与 CGRP 或其受体单克隆抗体预防偏头痛发作的间接比较：系统评价和荟萃分析。
CNS Drugs. 2021 Aug;35(8):805-820. doi: 10.1007/s40263-021-00834-9. Epub 2021 Jul 16.
4
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.美国头痛学会共识声明：更新将新的偏头痛治疗方法整合到临床实践中的建议。
Headache. 2021 Jul;61(7):1021-1039. doi: 10.1111/head.14153. Epub 2021 Jun 23.
5
Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review.加用阿那白滞素A的降钙素基因相关肽单克隆抗体疗法治疗慢性偏头痛患者的真实世界证据：一项回顾性图表审查
Pain Ther. 2021 Dec;10(2):809-826. doi: 10.1007/s40122-021-00264-x. Epub 2021 Apr 21.
6
Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine.降钙素基因相关肽靶向单克隆抗体药物作为依替巴肽治疗慢性偏头痛患者的附加疗法的疗效和耐受性。
Pain Med. 2021 Aug 6;22(8):1857-1863. doi: 10.1093/pm/pnab093.
7
Immunogenicity of biologic therapies for migraine: a review of current evidence.偏头痛生物治疗的免疫原性：当前证据综述。
J Headache Pain. 2021 Jan 7;22(1):3. doi: 10.1186/s10194-020-01211-5.
8
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial.依瑞奈尤单抗预防偏头痛的长期疗效和安全性：一项随机临床试验 5 年开放标签治疗阶段的结果。
Eur J Neurol. 2021 May;28(5):1716-1725. doi: 10.1111/ene.14715. Epub 2021 Jan 20.
9
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study.依普替扎umab 预防阵发性偏头痛：PROMISE-1 研究中治疗 1 年的持续疗效。
Clin Ther. 2020 Dec;42(12):2254-2265.e3. doi: 10.1016/j.clinthera.2020.11.007. Epub 2020 Nov 27.
10
Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis.依瑞奈尤单抗和肉毒毒素 A 联合治疗无先兆的难治性慢性偏头痛：一项回顾性分析。
J Pain Palliat Care Pharmacother. 2021 Mar;35(1):1-6. doi: 10.1080/15360288.2020.1829249. Epub 2020 Oct 30.
Zotero 插件